Results 11 to 20 of about 447,577 (315)
Clinical Journal of the American Society of Nephrology, 2008 Reporting estimated glomerular filtration rate (eGFR) with serum creatinine simply provides the information for which the serum creatinine was ordered in the first place. Mass or universal screening is not the purpose of eGFR reporting. Furthermore, such mass screening does not seem justified.
Michal L, Melamed +2 more
openaire +3 more sources
Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth [PDF]
Signal Transduction and Targeted Therapy, 2020 AbstractEpidermal growth factor receptor (EGFR) activation plays a pivotal role in EGFR-driven non-small cell lung cancer (NSCLC) and is considered as a key target of molecular targeted therapy. EGFR tyrosine kinase inhibitors (TKIs) have been canonically used in NSCLC treatment.
Nan Yao +14 more
openaire +2 more sources
Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas [PDF]
Clinical Cancer Research, 2021 Abstract Purpose: Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced gastroesophageal adenocarcinoma is poor. Randomized clinical trials failed to show a
Simona Corso +41 more
openaire +4 more sources
Analysis of Epithelial Growth Factor-Receptor (EGFR) Phosphorylation in Uterine Smooth Muscle Tumors [PDF]
, 2013 Uterine fibroids are the commonest uterine benign tumors. A potential mechanism of malignant transformation from leiomyomas to leiomyosarcomas has beendescribed.
Darius Dian +17 more
core +1 more source
EGFR‐AS1 Promotes Bladder Cancer Progression by Upregulating EGFR [PDF]
BioMed Research International, 2020 Long noncoding RNAs play an essential role in bladder cancer progression. The role of long noncoding RNA EGFR‐AS1 in bladder cancer needs further study. We used clinical specimens to analyze the relationship between EGFR‐AS1 and bladder cancer patients’ characteristics.
Anbang Wang +8 more
openaire +2 more sources
Clinical Journal of the American Society of Nephrology, 2009 GFR is the accepted metric for evaluating renal function but measuring it directly (mGFR) can be cumbersome, time-consuming, and costly. The constant infusion method using inulin as the filtration marker, introduced in 1934 by Richards and Smith (1), has undergone many revisions that have now made mGFR easier to perform, although not widely available ...
Richard J. Glassock +1 more
openaire +1 more source
Improved Biological Impacts of Anti-EGFR Monoclonal Antibody in KRAS-Mutant Colorectal Cancer Cells by Silica-Coated Magnetic Nanoparticle Conjugation [PDF]
Pharmaceutical SciencesBackground: The therapeutic potential of epidermal growth factor receptor (EGFR) targeting in colorectal cancer (CRC) is hindered by the presence of KRAS codon 12 activating mutations, prevalent in approximately 25% of advanced CRC cases.
Maedeh Yousefi +4 more
doaj +1 more source
Simulation of the regulation of EGFR endocytosis and EGFR‐ERK signaling by endophilin‐mediated RhoA‐EGFR crosstalk [PDF]
FEBS Letters, 2008 Deregulations of EGFR endocytosis in EGFR‐ERK signaling are known to cause cancers and developmental disorders. Mutations that impaired c‐Cbl–EGFR association delay EGFR endocytosis and produce higher mitogenic signals in lung cancer. ROCK, an effector of small GTPase RhoA was shown to negatively regulate EGFR endocytosis via endophilin A1.
Ung, C.Y. +6 more
openaire +2 more sources
Zhongliu Fangzhi Yanjiu, 2020 Objective To investigate whether the inhibition of EGFR nuclear transport could reduce the radioresistance of human cervical cancer cells. Methods Human cervical cancer CaSki and HeLa cells were exposed to radiation treated with or without Thr654 ...
LI Lu +6 more
doaj +1 more source
Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR [PDF]
Oncogene, 2012 Epidermal growth factor receptor (EGFR)-mediated cell signaling is critical for mammary epithelial cell growth and survival; however, targeting EGFR has shown no or only minimal therapeutic benefit in patients with breast cancer. Here, we report a novel regulatory mechanism of EGFR signaling that may explain the low response rates. We found that breast
Li, X +7 more
openaire +2 more sources